P. Leyssen

ACE2 mimetic antibody potently neutralizes all SARS-CoV-2 variants and fully protects in XBB.1.5 challenged monkeys

SARS-CoV-2 Omicron potently neutralized by a novel antibody with unique Spike binding properties

This paper identifies a potent human monoclonal antibody, P2G3, that neutralizes multiple SARS-CoV-2 variants including Omicron, and demonstrates its protective efficacy in a monkey model.

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.

Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen

This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

In Vitro Activity of Itraconazole Against SARS-CoV-2

This paper assesses the in vitro antiviral activity of itraconazole and its metabolite against SARS-CoV-2, finding EC50 values of 2.3 μM and 3.6 μM, respectively, and reports no clinical efficacy in hospitalized patients.

Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species

The paper identifies mutations in picornaviruses that confer resistance to vapendavir, including both pocket and non-pocket mutations, and shows some mutations require drug presence for viral replication.

STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters

This study shows that STAT2 signaling both restricts SARS-CoV-2 spread and causes severe pneumonia in infected hamsters.

Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication

This study identifies alpha-ketoamides as broad-spectrum inhibitors effective against coronavirus and enterovirus proteases, with compounds showing low-micromolar activity in cell cultures.

Preprint: Environmentally-Friendly Workflow Based on Supercritical Fluid Chromatography and Tandem Mass Spectrometry Molecular Networking For the Discovery of Potent Anti-Viral Leads From Plants

This paper develops a supercritical fluid chromatography and tandem mass spectrometry workflow to isolate and identify antiviral compounds from plant extracts, discovering two potent antiviral diterpene esters.